Tag: Cadila
Cadila Pharma marks three years of ThRabis, world’s first three-dose rabies...
ThRabis® was launched in April 2022 and has since been rolled out in multiple countries, offering a simpler, shorter vaccination schedule
Cadila Pharmaceuticals appoints Ashraf Allam as Global COO
An accomplished and well-regarded industry leader with more than three decades of experience, Mr. Allam was serving recently as the CEO at the Public Investment Fund
Jawed Zia appointed as CEO of Cadila Pharma
Zia will lead the strategy and business operations of Cadila’s branded prescriptions pharma business
Cadila Healthcare is now Zydus Lifesciences
Zydus unveils its ‘innovation and care’ centric corporate brand identity
Cadila Pharma expands its oncology portfolio with monoclonal antibody, Tarzed
TARZED is considered safe and more efficacious compared to conventional treatment medicines for breast cancer
Healthcare leaders at BRICS event call for partnership in infrastructure development
Partnership in infrastructure development at quick turnaround times is vital for India’s healthcare system..........................
Zydus Cadila vaccine candidate gets nod for Phase III clinical trials
The candidate has been supported by the National Biopharma Mission (NBM) under the aegis of BIRAC and the Department of Biotechnology, Government of India.......................
Zydus to begin Phase I trials of its inflammation drug, ZYIL1
Phase I trial will study the safety, tolerability, pharmacokinetics and pharmacodynamics of ZYIL1 in healthy human volunteers. Zydus has secured a Strong IP portfolio with multiple patents filed in all major countries.....................
Cadila Pharma launches Tikacad to address cardiac health issues
Tikacad® containing Ticagrelor reduces the rate of stent thrombosis in patients who have been stented for treatment of ACS. Ticagrelor can also be used for the primary prevention of stroke in patients with coronary artery disease as approved by the USFDA...............
Cadila launches Adalimumab biosimilar, Cadalimab in India
In an effort to strengthen their the biosimilar product portfolio, Cadalimab™ is the fourth biosimilar launched in the last 2 months by Cadila Pharmaceuticals..................